Pharmacokinetics of oligonucleotides

CIBA Foundation Symposia

Volumn , Issue 209, 1997, Pages 60-78

  Agrawal, Sudhir ^a   Zhang, Ruiwen ^b  

^a HYBRIDON INC   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; METHYLPHOSPHONIC ACID; NUCLEOTIDE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL; CHEMISTRY; CONFORMATION; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; ORGANOPHOSPHORUS COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

EID: 0031300863     PISSN: 03005208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Agrawal S 1996 Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14: 376-387
2. Agrawal S, Zhang R 1997 Pharmacokinetics of phosphorothioate oligonucleotide and its novel analogs. In: Weiss B (ed) Antisense oligonucleotides and antisense RNA: novel pharmacological and therapeutic agents. CRC Press, Boca Raton, FL, p 57-78
3. Agrawal S, Mayrand SM, Zamecnik PC, Pederson T 1990 Site-specific excision from RNA by RNase H and mixed phosphate backbone oligodeoxynucleotides. Proc Natl Acad Sci USA 87:1401-1405
4. Agrawal S, Temsamani J, Tang J-Y 1991 Pharmacokinetics biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599
5. Agrawal S, Temsamani J, Galbraith W, Tang J-Y 1995a Pharmacokinetics of antisense oligonucleotides. Clin Pharmacol 28:7-16
6. Agrawal S, Temsamani J, Tang J-Y 1995b Self-stabilized oligonucleotides as novel antisense agents. In: Akhtar S (ed) Delivery strategies for antisense oligonucleotide therapeutics. CRC Press, New York, p 105-122
7. Agrawal S, Zhang X, Lu Z et al 1995e Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50:571-576
8. Agrawal S, Tan W, Jiang Z, Yu D, Iyer RP 1996 Synthetic methods for the radioisotopic labeling of oligonucleotides. In: Schlingensiepen KH (ed) Antisense oligonucleotide from technology to therapy. Blackwell, Berlin, p 60-77
9. Agrawal S, Jiang Z, Zhao Q et al 1997a Mixed-backbone oligonucleotides as second-generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 94:2620-2625
10. Agrawal S, Tan W, Cai W, Xie X, Zhang R 1997b In vivo pharmacokinetics of phosphorothioate oligonucleotides containing continuous guanosines. Antisense Nucleic Acid Drug Dev 7:245-249
11. Akhtar S, Agrawal S 1997 In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 18:12-18
12. Chem TL, Miller P, Ts'O POP, Colvin OM 1990 Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single IV injection in mice. Drug Metab Dispos 18:815-818
13. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190
14. Crooke ST, Graham MJ, Zuckerman JE et al 1996 Pharmacokinetic properties of several novel oligonucleotides analogs in mice. J Pharmacol Exp Ther 277:923-937
15. Devlin T, Iyer RP, Johnson S, Agrawal S 1996 Mixed backbone oligonucleotides containing internucleotide primary phosphoramidate linkages. Bioorg Med Chem Lett 6:2663-2668
16. Goodchild J, Zamecnik PC, Kim B 1991 The clearance and degradation of oligodeoxynucleotide following intravenous injection into rabbits. Antisense Res Dev 1:153-160
17. Iversen PL, Mata J, Tracewell WG, Zon G 1994 Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in adult male rat following single injections and continuous infusion. Antisense Res Dev 4:43-52
18. Iyer RP, Yu D, Jiang Z, Agrawal S 1996 Synthesis, biophysical properties and stability studies of mixed backbone oligonucleotides containing segments of methylphosphotriester internucleotide linkages. Tetrahedron 52:14419-14436
19. Metelev V, Lisziewicz J, Agrawal S 1994 Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg Med Chem Lett 4:2929-2934
20. Monia BP, Lesnik EA, Gonzalez C et al 1993 Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514-14522
21. 3H-labeled oligonucleotides I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932-943
22. Tang J-Y, Temsamani J, Agrawal S 1993 Self-stabilized antisense oligonucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res 21:2729-2735
23. Temsamani J, Tang J-Y, Padmapriya AA, Kubert M, Agrawal S 1993 Pharmacokinetics biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev 3:277-284
24. Temsamani J, Roskey A, Chaix C, Agrawal S 1997 In vivo metabolic profile of a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:159-165
25. Zamecnik PC 1996 History of antisense oligonucleotides. In: Agrawal S (ed) Antisense therapeutics. Humana Press, Totowa, NJ, p 1-12
26. Zhang R, Diasio RB, Lu Z et al 1995a Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49:929-939
27. Zhang R, Yan J, Shahinian H et al 1995b Pharmacokinetics of an anti-human immunodeficiency virus antisense oligonucleotide phosphorothioate (GEM 91) in HIV-1 infected subjects. Clin Pharmacol Ther 58:44-53
28. Zhang R, Lu Z, Zhang X et al 1995c Stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem 41:836-843
29. Zhang R, Lu Z, Zhang H et al 1995d In vivo stability and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem Pharmacol 50:545-556
30. Zhang R, Iyer RP, Yu D et al 1996 Pharmacokinetics and tissues disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther 278:971-979
31. Zhao H, Lu Z, Diasio RB, Agrawal S, Zhang R 1995 Biliary excretion of oligonucleotides: previously unrecognized pathway in metabolism of antisense oligonucleotides. FASEB J 3:A410